Adicet Bio Announces First Quarter 2026 Financial Results and Corporate Progress Updates
Adicet Bio has reported financial results and operational progress for the first quarter ended March 31, 2026, highlighting continued advancement across its pipeline of allogeneic gamma delta T cell therapies targeting autoimmune diseases and cancer. The company emphasized upcoming clinical milestones for its lead autoimmune candidate, ongoing expansion of its solid tumor portfolio, and continued development of next-generation cell therapy technologies.
Adicet Bio is focused on the discovery and development of off-the-shelf gamma delta CAR-T cell therapies designed to treat autoimmune disorders, hematologic malignancies, and solid tumors. The company’s platform centers on engineered gamma delta 1 T cells, which are intended to combine the potency of cellular immunotherapy with the scalability and accessibility advantages of allogeneic manufacturing approaches.
Chen Schor, President and Chief Executive Officer of Adicet Bio, stated that the company is approaching what he described as a major inflection point as it prepares to release new Phase 1 clinical data for its lead product candidate, prula-cel, during mid-2026.
According to Schor, the upcoming clinical update is expected to include data from at least 20 patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE), each with a minimum of six months of follow-up. He noted that the anticipated data release represents an important milestone for the company and reflects the collaborative efforts of Adicet employees, investigators, and clinical trial sites participating in the ongoing study.
Schor described prula-cel as a potentially first-in-class gamma delta 1 CAR-T cell therapy being evaluated for autoimmune diseases. He emphasized that the company’s Phase 1 clinical program has been designed to generate comprehensive safety and efficacy data across multiple autoimmune conditions.
In addition to its autoimmune disease programs, Schor said the company continues to advance its broader pipeline, including the development of ADI-212, a next-generation armored and gene-edited cell therapy candidate designed for solid tumors. He also highlighted ongoing preclinical efforts focused on a differentiated in vivo CAR-T platform targeting hematologic malignancies.
One of the company’s primary near-term priorities remains the advancement of prula-cel in autoimmune diseases, particularly lupus nephritis and systemic lupus erythematosus. Adicet announced that it plans to provide a clinical update from the ongoing Phase 1 trial in mid-2026.
The study is evaluating prula-cel across multiple autoimmune conditions and is intended to assess safety, tolerability, pharmacodynamics, and preliminary clinical activity. According to the company, the upcoming data presentation will include patients with lupus nephritis and systemic lupus erythematosus who have been followed for at least six months after treatment.
Adicet also disclosed plans to meet with the U.S. Food and Drug Administration during the second quarter of 2026 to discuss the potential design of future pivotal clinical trials for prula-cel. Pending regulatory feedback and clearance, the company expects to begin startup activities for a pivotal program in lupus nephritis or combined lupus nephritis and systemic lupus erythematosus populations during the second half of 2026.
The company further noted that, following discussions with the FDA in November 2025, patients with lupus nephritis and systemic lupus erythematosus participating in the ongoing Phase 1 study and future trials may now receive prula-cel treatment in outpatient settings. This development could potentially improve treatment accessibility and simplify administration logistics for patients and healthcare providers.
In addition to lupus-related indications, Adicet plans to provide another clinical update in the second half of 2026 involving patients with systemic sclerosis, another autoimmune disease being evaluated within the company’s broader clinical development strategy.
The company is also continuing a separate Phase 1 study of prula-cel in treatment-refractory rheumatoid arthritis. This trial is designed to evaluate reduced-intensity lymphodepletion regimens prior to cell therapy administration.
Specifically, the study is assessing two conditioning approaches: cyclophosphamide alone and cyclophosphamide combined with fludarabine. Lymphodepletion is commonly used before CAR-T cell therapy administration to improve expansion and persistence of therapeutic cells.
Primary endpoints for the rheumatoid arthritis trial include safety and tolerability assessments, while secondary analyses focus on cellular kinetics, pharmacodynamic biomarkers, and measures of disease activity. Adicet expects to provide the next update from this program during the second half of 2026.
Beyond autoimmune diseases, Adicet continues advancing its oncology pipeline, particularly in solid tumors where cell therapy development has historically faced significant challenges related to tumor microenvironment suppression, cellular persistence, and therapeutic durability.
The company announced plans to submit a regulatory filing for ADI-212 during the third quarter of 2026, with Phase 1 clinical enrollment anticipated to begin in the fourth quarter of 2026, pending regulatory clearance.
ADI-212 is being developed for metastatic castration-resistant prostate cancer (mCRPC), an advanced form of prostate cancer that remains difficult to treat despite advances in targeted therapies and immunotherapy approaches.
The therapy targets prostate-specific membrane antigen (PSMA), a protein highly expressed on prostate cancer cells and a widely studied target within prostate cancer drug development.
According to Adicet, ADI-212 incorporates several advanced engineering features designed to improve activity against solid tumors. The therapy includes a novel CAR binder intended to improve tumor recognition and potentially enhance tolerability.
The candidate also incorporates membrane-tethered interleukin-12 (IL-12) armoring, a strategy intended to strengthen anti-tumor immune responses within the tumor microenvironment. Additionally, ADI-212 utilizes CRISPR/Cas9-mediated disruption of mediator complex subunit 12 (MED12), a gene-editing modification designed to improve potency and resistance to suppressive tumor conditions.
The company believes these combined engineering approaches could enable ADI-212 to deliver multiple anti-tumor mechanisms of action simultaneously within solid tumors, an area where conventional CAR-T therapies have faced substantial limitations.
Adicet’s broader pipeline also includes several earlier-stage gamma delta CAR-T cell therapy programs targeting autoimmune diseases, hematologic cancers, and solid tumors. The company continues investing in platform innovation and next-generation technologies intended to improve the effectiveness, scalability, and accessibility of allogeneic cellular therapies.
Among these efforts are ongoing preclinical programs focused on in vivo CAR-T technologies targeting hematologic malignancies. Unlike traditional ex vivo CAR-T manufacturing approaches, in vivo CAR-T strategies aim to engineer immune cells directly within the patient’s body, potentially simplifying manufacturing processes and expanding patient access.
In addition to operational updates, Adicet reported financial results for the first quarter of 2026.
Research and development expenses totaled $17.5 million for the quarter ended March 31, 2026, compared with $22.8 million during the same period in 2025. The company stated that the decrease was primarily driven by a $3.6 million reduction in payroll and personnel-related expenses associated with lower headcount.
Additional decreases included a $1.4 million reduction in laboratory supply and material expenses, a $0.5 million decrease in contract research organization (CRO) expenses, and a $0.2 million decline in allocated facility-related costs. These reductions were partially offset by a $0.4 million increase in professional fees.
General and administrative expenses were reported at $4.1 million for the first quarter of 2026, compared with $7.1 million during the same quarter of 2025. The decline was attributed primarily to lower payroll and personnel costs, including reduced stock-based compensation and decreased headcount.
The company also reported reductions in allocated facility-related expenses and professional fees within its general and administrative functions.
Adicet reported a net loss of $20.2 million for the quarter, equivalent to a net loss of $1.88 per basic and diluted share. This compares with a net loss of $28.2 million, or $4.96 per share, during the first quarter of 2025.
The first quarter 2026 results included non-cash stock-based compensation expenses of $1.3 million, compared with $3.2 million during the same period the previous year.
As of March 31, 2026, Adicet held cash, cash equivalents, and short-term investments totaling $137.6 million, compared with $158.5 million as of December 31, 2025.
The company stated that its current cash position is expected to support operating expenses into the second half of 2027, providing runway to advance key clinical programs, regulatory interactions, and ongoing platform development activities.
The coming year is expected to be particularly important for Adicet as it approaches multiple clinical and regulatory milestones across both autoimmune and oncology indications. The anticipated Phase 1 data updates for prula-cel could provide important insight into the potential role of gamma delta CAR-T therapies in autoimmune disease treatment, an emerging area of interest within the broader cell therapy field.
At the same time, the planned advancement of ADI-212 into clinical testing reflects the company’s continued commitment to expanding the capabilities of engineered cell therapies beyond hematologic malignancies and into solid tumors, one of the most challenging frontiers in cancer immunotherapy development.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients.
